Overview
The European Lung Cancer Congress (ELCC) 2026 Highlights Webinar will provide an expert overview of the most impactful research and clinical updates presented at ELCC. This session will highlight key advances in the biology, prevention, early detection, diagnosis, and multidisciplinary management of thoracic malignancies. Faculty will review emerging data from translational and clinical studies and discuss evolving approaches in lung cancer screening, precision medicine, surgical and non-surgical treatment strategies, systemic therapies, and supportive care. Join us for a curated discussion of the findings most likely to influence clinical practice and future research.
- Summarize the latest clinical data on KRAS, EGFR, and HER2-targeted therapies in lung cancer and their implications for treatment selection.
- Evaluate recent advances in small cell lung cancer (SCLC) management and the emerging role of antibody-drug conjugates (ADCs).
- Discuss new developments in immunotherapy and treatment strategies for early-stage lung cancer.
9:00am: Welcome – Moderators Alona Zer and Helena Linardou
9:00-9:15: Adrian Sacher - KRAS, EGFR, HER2 Highlights - 1O, 4MO, 5MO
9:15-9:30: Giannis Mountzios - SCLC and ADCs Highlights
9:30-9:45: Jaruska Naidoo - Immunotherapy and Early-Stage Highlights
9:45-9:55: Antonio Passaro - Scientific Chair Review
9:55-10:10: All - Panel Q&A
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- Summarize the latest clinical data on KRAS, EGFR, and HER2-targeted therapies in lung cancer and their implications for treatment selection.
- Evaluate recent advances in small cell lung cancer (SCLC) management and the emerging role of antibody-drug conjugates (ADCs).
- Discuss new developments in immunotherapy and treatment strategies for early-stage lung cancer.
9:00am: Welcome – Moderators Alona Zer and Helena Linardou
9:00-9:15: Adrian Sacher - KRAS, EGFR, HER2 Highlights - 1O, 4MO, 5MO
9:15-9:30: Giannis Mountzios - SCLC and ADCs Highlights
9:30-9:45: Jaruska Naidoo - Immunotherapy and Early-Stage Highlights
9:45-9:55: Antonio Passaro - Scientific Chair Review
9:55-10:10: All - Panel Q&A
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Share
Participants
Committee Member
Metropolitan Hospital
Alona Zer
Committee Member
Rambam Health Care Campus
Committee Member
Henry Dunant Hospital Center
Jarushka Naidoo
MD
Professor of Medical Oncology
Royal College of Surgeons
Consultant, Medical Oncologist at Beaumont Hospital